GlassScriptPhysician profile
Amy R Cavner
NPI 1427712421
$2,778.21
in general payments reported to CMS, 2019-2025
20 companies · $911 in 2025
The $911 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $321 · 2023: $464 · 2024: $1,083 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,457.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $503.83 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $414.45 | 2024-2025 | Spravato |
| Novo Nordisk INC | $363.44 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $361.78 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbvie INC. | $175.99 | 2022-2025 | |
| Exact Sciences Corporation | $151.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $129.91 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $123.99 | 2024 | Evenity |
| Lexicon Pharmaceuticals, INC. | $115.21 | 2024 | Inpefa |
| Lilly USA, LLC | $93.28 | 2022-2025 | Mounjaro, Jardiance, Lyumjev |
| Otsuka America Pharmaceutical, INC. | $82.12 | 2022-2025 | Rexulti |
| Lundbeck LLC | $53.11 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $35.51 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $33.99 | 2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.50 | 2025 | Caplyta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $30.68 | 2024 | Gemtesa |
| Sage Therapeutics, LLC | $23.37 | 2023 | |
| Edwards Lifesciences Corporation | $21.45 | 2023 | |
| Corcept Therapeutics | $21.20 | 2025 | Korlym |
| Inogen, INC. | $9.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cavner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.